Novo Nordisk Launches Aggressive Pricing Strategy for Wegovy Amid Restructuring

Novo Nordisk introduces a $249/month Wegovy subscription to boost patient loyalty and undercut Eli Lilly, while cutting 400 US manufacturing jobs as part of a global cost-reduction plan.

In a bold move within the highly competitive weight-loss drug market, Danish pharmaceutical giant Novo Nordisk is implementing a new subscription-based pricing model for its blockbuster medication, Wegovy. The strategy aims to secure long-term patient loyalty and directly undercut rival Eli Lilly, while management concurrently enacts a significant cost-cutting program impacting US manufacturing operations.

Subscription Model Targets Patient Retention

To provide predictable costs for self-paying patients, the company initiated a multi-tiered subscription program in late March. Patients committing to a full year will pay $249 per month for the Wegovy pen. This price undercuts the lowest monthly price offered by competitor Eli Lilly by approximately $50. The initiative directly addresses a major challenge with GLP-1 medications: a high first-year discontinuation rate, frequently driven by fluctuating costs.

The strategic shift has been well-received by investors. The announcement bolstered a recent share price recovery, with the stock gaining nearly five percent on a weekly basis to reach €31.96. Analysts suggest the subscription model, coupled with stricter US Food and Drug Administration (FDA) actions against cheaper copycat drugs, could stabilize demand for the original product. For Novo Nordisk, the newly introduced Wegovy pill represents a critical opportunity to rapidly capture market share from patients previously reluctant to use injectable treatments.

Cost-Cutting Measures Hit US Manufacturing

Parallel to its commercial offensive, the company is aggressively tackling expenses. At its production facility in Bloomington, Indiana, Novo Nordisk will eliminate around 400 positions by early May—roughly one-fifth of the site's workforce. The plant, acquired in 2024 as part of the multi-billion dollar Catalent takeover, has recently faced substantial operational hurdles. Manufacturing bottlenecks and an FDA warning letter concerning potential contamination issues had previously caused delays for several clients.

The US job cuts form part of a broader global restructuring plan. By the end of 2026, CEO Mike Doustdar aims to reduce the global workforce by approximately 9,000 positions. This restructuring is designed to lower the annual cost base by the equivalent of $1.3 billion. The freed-up capital is intended to be reinvested directly into strengthening the company's core diabetes and obesity divisions, thereby securing its commercial competitive edge.